Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

Northern, thanks for your expressing your view re ICER

I think most here are 'moving targets' in a sense. I know I am as I'm trying to fathom complexities re the science, how things work in the real world of medical care, etc. I don't claim any special expertise/knowledge either.

I like to see different/opposing views as long as they are authentic/honest.

My objection to the report is that I believe both Lupkynis and Benlysta received the same overall rating when clearly Lupkynis is far superior in its ability to rapidly bring a complete or partial response to patients.

I don't want doctors to think they're similar re efficacy, as that means a high likelihood that some MD's will prescribe Benlysta in error.

The net result of that would be that patients suffer, just as they will if the ICER report were used to by payers to deny patient access to Lupkynis.

Since GSK is represented within ICER (and Aurinia is not), I suspect they have a hand in getting a higher rating than deserved.

All above is simply my opinion as well.

BTW, VOS is Aurinia's DES drug, VCS is Aurinia's term for voclosporin, although most refer to it as VOC

cheers